The latest study will test setidegrasib versus docetaxel in second-line lung cancer.
ApexOnco Front Page
Recent articles
What could be the four HengRui assets picked up by Bristol?
Another SERD catalyst and the son of Darzalex take centre stage.
Tough equity markets as well as competitor developments prompt a narrowed focus.
Giredestrant will soon become the first oral SERD to yield first-line data.
The company hits an FDA-mandated enrolment target, but only in follicular lymphoma.
But this adds another complexity, and has camizestrant really scored a first-line win?
The company is starting a phase 3 trial of sacituzumab tirumotecan in first-line TNBC.